

Revusiran sodium

| | |
|-----------|---|
| Cat. No.: | HY-132590A |
| Target: | Small Interfering RNA (siRNA); Transthyretin (TTR) |
| Pathway: | Epigenetics; Neuronal Signaling |
| Storage: | Please store the product under the recommended conditions in the Certificate of Analysis. |

Revusiran (sodium)

BIOLOGICAL ACTIVITY

Description

Revusiran sodium is a 1st-generation short interfering RNA, which directed against transthyretin (TTR) mRNA. Revusiran sodium can be used for transthyretin (TTR)-mediated amyloidosis research^[1].

REFERENCES

[1]. Jessica E Sutherland, et al. Nonclinical Safety Profile of Revusiran, a 1st-Generation GalNAc-siRNA Conjugate for Treatment of Hereditary Transthyretin-Mediated Amyloidosis. *Nucleic Acid Ther.* 2020 Feb;30(1):33-49.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA